Angus Brayne
About Angus Brayne
Angus Brayne is an Advanced AI Scientist at BenevolentAI in London, with a background in computational statistics, machine learning, and physics.
Company: BenevolentAI
Angus Brayne is currently an Advanced AI Scientist at BenevolentAI in London, England. His role involves extensive research and development in artificial intelligence, particularly in the application of AI for drug discovery and medical research. He has been with the company since 2019, starting as a Machine Learning Research Intern, then progressing to an AI Scientist, and now holds a senior position.
Title: Advanced AI Scientist
As an Advanced AI Scientist at BenevolentAI, Angus Brayne focuses on creating and implementing innovative AI-driven solutions to complex problems in healthcare and drug discovery. His work includes developing advanced machine learning algorithms and mentoring junior scientists and interns within the organization.
Education and Expertise: UCL and University of Oxford
Angus Brayne holds an MSc in Computational Statistics and Machine Learning from UCL, completed in 2019. He also earned an MPhys in Physics from the University of Oxford, which he completed in 2017. His academic background provides a strong foundation in both theoretical and applied aspects of machine learning and artificial intelligence.
Achievements: Research and Recognition
Angus Brayne authored a research paper on AI applications in drug discovery, published in a leading scientific journal. In 2022, he received the 'Innovator of the Year' award at BenevolentAI for his significant contributions to AI research. Additionally, he presented his work on machine learning advancements in medical research at the AI in Healthcare Summit in 2022.
Professional Background: Internships and Early Career
Before his current role at BenevolentAI, Angus Brayne gained experience through various internships. He worked as a Quantitative Research Summer Intern at Virtu Financial and KCG Holdings, Inc. in 2017, a Quantitative Management Summer Analyst at Bank of America Merrill Lynch in 2016, a Risk Intern at RenaissanceRe in 2015, and a Tech Futures Intern at Sky in 2014. These diverse roles equipped him with a broad skill set in quantitative analysis and risk management.
Projects: AI in Drug Discovery
During his tenure at BenevolentAI, Angus Brayne developed a novel machine learning algorithm that significantly improved the accuracy of predictive models used in drug discovery processes. His innovative approach has contributed to enhancing the efficiency and efficacy of research within the company.